Press Releases

Discovery Park Ventures invests £100K in new tenant Vox Imaging Technology to advance ophthalmic imaging for preclinical research

Discovery Park Ventures (DPV) announces an investment of £100K into Vox Imaging Technology Ltd. (VIT), an ambitious ophthalmic technology company looking to transform eye imaging in preclinical research and improve drug discovery and development. Its compact and customisable instrument is believed to be the first scanning laser ophthalmoscope especially designed for laboratory use, able to produce high-quality data rapidly.

Pharmapack Report Predicts Major Innovation for Inhaled Pulmonary and Intra Nasal Drug Delivery in 2024

First Health Advisory Adds Distinguished Board to Pilot Cyber Health Growth

Amerigo Scientific Released A Well-Selection ELISA Kits Featured with Simplicity and Consistency

Amerigo Scientific is pleased to announce the availability of their well-selection and high-quality optimized ELISA kits designed to accurately measure target-specific proteins with simplicity, reliability, and consistency.

Verisense Health Launches Research-Grade Smart Watch, Smashing Previous Price/Performance Benchmarks

Verisense Health combined its wearable technology expertise and clinical research knowledge to satisfy this unmet market need.

Johari Digital Healthcare Limited Welcomes Mr. Suhas Tamras as New Chief Executive Officer

Johari Digital Healthcare appoints Mr. Suhas Tamras as CEO. With 25+ years in medical device leadership, his proven success aligns with JDHL's commitment to excellence. Excited about global impact, Mr. Tamras pledges growth and innovation, marking a new era for JDHL.

CD Biosciences Launches Substrate-Chromogens for Immunohistochemistry

CD BioSciences announced the launch of Chromogenic Substrates for immunohistochemistry (IHC).

Telomere Length Aging Clocks Help to See the Unseen in Aging

Rdcthera Announces RDC Development and Analysis Services Based on Its Technology Platform

Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

Creative Diagnostics has announced P53 and TP53 antibodies and solutions to support cancer research.

STEMart Launches New Force Degradation Services to Ensure Drug Stability and Safety

STEMart announced the launch of its new Force Degradation Services.

Creative BioMart Enlarged Its Offerings for Recombinant F3 Protein

Lifeasible Unveils Comprehensive Exosome Identification Services for Accurate Characterization and Quantification

Inceptua Group and Cycle Pharmaceuticals Partner for a Free Goods Programme for Patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU)

Inceptua Group and Cycle Pharmaceuticals Ltd have announced a partnership to make NITYR® Tablets available via a Free Goods Programme for eligible patients with Hereditary Tyrosinemia Type 1 and Alkaptonuria.

To Fight Superbugs, Ace Infectious Unveils Phage Therapy Development Services

CD Formulation Excels in Developing and Optimizing Micro-Reservoir Controlled-Release Drug Delivery Systems

Alfa Chemistry Introduces Bio-based Polymers, Responding to Market Demand

Digital Health Panel Developer Verisense Health Appoints New Engineering Manager in Malaysia

Chong Toh Ying has more than 16 years’ experience managing large datasets and building and leading software engineering teams that deliver fast and accurate results.

Huateng Pharma Launches Veterinary Solutions – Fluralaner and Sarolaner

Huateng Pharm offers Fluralaner (CAS NO.: 864731-61-3) and Sarolaner (CAS NO.: 1398609-39-6) from laboratory-scale development to commercial production.

PathAI Commences New Year with Strong Foundation for Growth Following Key 2023 Achievements in AI-Powered Pathology Products, Strategic Partnerships, and Leadership Team Hires

PathAI, a leading AI-powered precision pathology company, has concluded a year marked by significant growth and advancements. The company developed and launched over 20 new AI products across oncology, MASH/MASLD and IBD; launched the AISight® image management system (IMS); distributed the AISight platform and IMS to a growing footprint of more than 50 labs globally; expanded clinical trial services to encompass MASH/MASLD, IBD and oncology; and honed its leadership team to drive biopharma business, regulatory strategy, and growth initiatives. Moreover, PathAI established key partnerships, presented new data at major industry conferences, and was recognized through several industry awards. The culmination of these 2023 achievements serves to further revolutionize the field of pathology, bringing more AI-driven tools to drug development and diagnostics.